| P2093 | author name string | D M Roden | |
| | G R Wilkinson | |
| | B Leake | |
| | M F Fromm | |
| | R B Kim | |
| | A J Wood | |
| | C Wandel | |
| P2860 | cites work | Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase | Q28325776 |
| | Biochemistry of multidrug resistance mediated by the multidrug transporter | Q29616476 |
| | Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites | Q33832954 |
| | Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs | Q34059522 |
| | Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833 | Q34065489 |
| | P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells | Q34538994 |
| | Expression of a multidrug-resistance gene in human tumors and tissues | Q34586576 |
| | Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes | Q35608569 |
| | Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine | Q36031211 |
| | P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs | Q37355653 |
| | P-glycoprotein and pharmacokinetics | Q40532601 |
| | The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications | Q40947744 |
| | Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. | Q41002448 |
| | Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers | Q41078148 |
| | Clinical trials of P-glycoprotein reversal in solid tumours | Q41078214 |
| | HIV-1 protease inhibitors. A review for clinicians | Q41303053 |
| | Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. | Q41322435 |
| | Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy | Q42275470 |
| | Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein | Q42552510 |
| | Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. | Q42930123 |
| | Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group | Q45771512 |
| | Brain viral burden in HIV infection. | Q46003548 |
| | Measurement of CNS HIV burden and its association with neurologic damage | Q48228478 |
| | A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). | Q52306238 |
| | Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors | Q52537121 |
| | Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry | Q71467046 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 289-294 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors | |
| P478 | volume | 101 | |